



E-News | October 28, 2022 | Vol 12, No 7

2022 Fall Hybrid Group Meeting Convenes Next Week in Chicago



The Alliance for Clinical Trials in Oncology will convene the 2022 Alliance Fall Hybrid Group Meeting November 2-5. The four-day meeting will host a variety of scientific and administrative sessions led by distinguished oncology researchers, clinical trial specialists, and administrators from across the country. [Read more.](#)

Alliance Participant Engagement Portal

Update on Alliance Initiatives



The Alliance Participant Engagement Portal (PEP) is a web-based tool with the overarching goal of connecting trial participants to their clinical trial as well as providing bidirectional communication at key touch points throughout the trial. The PEP focuses on empowerment of Alliance clinical trial participants across all demographics and populations. Through engagement of participants in selected trials, we can learn from their journey to help researchers help other patients. [Read more.](#)



[Learn more about active Alliance lung cancer trial](#)

- **A021901 (Bronchial Neuroendocrine Tumors)**
- **A081801 (ALCHEMIST chemo-IO)**
- **A082002 (Advanced Non-small Cell Lung Cancer)**
- **A151216 (ALCHEMIST)**
- **A171901 (Non-small Cell Lung Cancer in Older Adults)**

Spotlight on Alliance Trials

Ongoing Trials

- **A011801 (COMPASS HER2 RD/Breast Cancer)**
- **A021602 (CABINET/Advanced Neuroendocrine Tumors)**
- **A021804 (Advanced Pheochromocytoma and Paraganglioma)**
- **A031902 (CASPAR/Metastatic Castration-resistant Prostate Cancer)**

Closed to Accrual

- **A031102 (Relapsed or Refractory Germ Cell Tumors)**

October ASCO Plenary Series

- **AFT-05 (PALbociclib CoLaborative Adjuvant Study (PALLAS))**



Alliance for Clinical Trials in Oncology | Office of the Group Chair, 221 Longwood Avenue, Room 108,
Boston, MA 02115

[Unsubscribe {recipient's email}](#)

[Constant Contact Data Notice](#)

Sent by donotreply@alliancencn.org powered by